Healthcare Equipment and Supplies
Company Overview of Interpace Diagnostics Corporation
Interpace Diagnostics Corporation operates a molecular diagnostics company that helps physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG platform. Its PathfinderTG platform uses advanced clinical algorithms to accurately stratify patients according to risk of cancer by assessing panels of DNA abnormalities in patients who have lesions (i.e., cysts or solid masses) with potential for cancer. Interpace Diagnostics Corporation was formerly known as RedPath Integrated Pathology, Inc. The company was founded in 2004 and is headquartered in Parsippany, New Jersey. As of October 31, 2014, Interpace Diagnostics Corporation ope...
300 Interpace Parkway
Morris Corporate Center 1
Parsippany, NJ 07054
Founded in 2004
Key Executives for Interpace Diagnostics Corporation
Founder and Chief Scientific Officer
Director of Sales & Marketing
Director of Cytology & Clinical Chemistry and Associate Molecular Laboratory Director
Director of Clinical Development
Compensation as of Fiscal Year 2015.
Interpace Diagnostics Corporation Key Developments
RedPath Integrated Pathology Announces Departure of Dennis Smith as President and CEO at the End of November 2014
Nov 7 14
PDI Inc. has acquired RedPath Integrated Pathology that tests for gastrointestinal, pancreatic and other cancer risks. Dennis Smith, M.D., RedPath president and CEO is departing at the end of the November 2014 but will remain an adviser to PDI's board.
RedPath Integrated Pathology, Inc. Launches Accucea Chemistry Test for Pancreatic Cyst Patients
Feb 18 14
RedPath Integrated Pathology, Inc. announced the launch of a new, patent-pending, customized test to accurately measure carcinoembryonic antigen in all pancreatic cyst fluids. Unlike routinely used, commercially available CEA assays, AccuCEA(TM) provides accurate results, even in pancreatic cyst fluid specimens with limited volume and/or high viscosity. Furthermore, AccuCEA provides physicians with more options in the diagnostic work-up of patients by preserving precious fluid and making it available for additional tests. When the amount of pancreatic cyst fluid is limited and CEA testing is prescribed, CEA can be analyzed in diluted fluid. However, dilution of cyst fluid can significantly impact the analytical accuracy of the resulting CEA measurements. RedPath has solved this problem by creating AccuCEA, which provides CEA measurements in diluted cyst fluid that are true to their corresponding neat (undiluted) cyst fluid CEA measurements. Results of the study documenting the accuracy of AccuCEA were presented at the 2013 Digestive Disease Week meeting.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries